| Title |
Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States
|
|---|---|
| Published in |
Cancer Epidemiology, Biomarkers & Prevention, January 2018
|
| DOI | 10.1158/1055-9965.epi-17-0523 |
| Pubmed ID | |
| Authors |
Jennifer L. Lund, Hanna K. Sanoff, Sharon Peacock Hinton, Hyman B. Muss, Virginia Pate, Til Stürmer |
| Abstract |
Older adults are often exposed to multiple medications, some of which could be inappropriate or have the potential to interact with each other. Older cancer patients may be at increased risk for medication-related problems due to exposure to cancer-directed treatment. We described patterns of potentially inappropriate medication (PIM) use and potential drug-chemotherapy interactions among adults age 66+ years diagnosed with stage I-III breast, stage II-III colon, and stage I-II lung cancer. Within the Surveillance, Epidemiology, and End Results-Medicare database, patients had to have Medicare Part D coverage with 1+ prescription in the diagnosis month and Medicare Parts A/B coverage in the prior 12 months. We estimated monthly prevalence of any and cancer-related PIM from 6 months pre- to 23 months post-cancer diagnosis and 12-month period prevalence of potential drug-chemotherapy interactions. Overall, 19,318 breast, 7,283 colon, and 7,237 lung cancer patients were evaluated. Monthly PIM prevalence was stable pre-diagnosis (37-40%), but increased in the year following a colon or lung cancer diagnosis, and decreased following a breast cancer diagnosis. Changes in PIM prevalence were driven primarily by cancer-related PIM in patients on chemotherapy. Potential drug-chemotherapy interactions were observed in all cohorts, with prevalent interactions involving hydrochlorothiazide, warfarin, and proton-pump inhibitors. There was a high burden of potential medication-related problems among older cancer patients; future research to evaluate outcomes of these exposures are warranted. Older adults diagnosed with cancer have unique medication management needs. Thus, pharmacy specialists should be integrated into multidisciplinary teams caring for these patients. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 68 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 16% |
| Student > Ph. D. Student | 8 | 12% |
| Student > Master | 5 | 7% |
| Student > Postgraduate | 4 | 6% |
| Researcher | 4 | 6% |
| Other | 8 | 12% |
| Unknown | 28 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 19% |
| Medicine and Dentistry | 11 | 16% |
| Nursing and Health Professions | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Psychology | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 31 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2021.
All research outputs
#15,994,393
of 25,746,891 outputs
Outputs from Cancer Epidemiology, Biomarkers & Prevention
#3,095
of 4,866 outputs
Outputs of similar age
#250,494
of 451,688 outputs
Outputs of similar age from Cancer Epidemiology, Biomarkers & Prevention
#21
of 47 outputs
Altmetric has tracked 25,746,891 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,866 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.5. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,688 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.